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Abstract The incidence of cardiovascular disease due to thrombosis is 2–4 folds greater
in diabetic patients. Prothrombin time, activated partial thromboplastin time
and platelet count are hematological indices that give an insight into the
coagulation status. Hence, this study aims to assess the coagulation status of
type II diabetic patients.
A comparative cross-sectional study was conducted at Bahir Dar Felege Hiwot re-
ferral hospital, Northwest Ethiopia. A total of 40 treated type II diabetic, 40 untreated
diabetics and 40 non-diabetic subjects were included. After taking informed consent,
structured questionnaire was used to collect socio-demographic data. Following in-
terview, 4 ml of blood was collected to determine PT, aPTT and platelet count of the
three groups. The data were entered into SPSS version 20 and analyzed. One-way
ANOVA was used to compare means of PT, aPTT and platelet count among the
groups. A P value less than 0.05 was considered as statistically significant.
The mean aPTT of non-diabetic, treated and untreated type II diabetic patient was
32.8 ± 4.12 s, 34.4 ± 5.3 s, and 25.42 ± 8.46 s, respectively. The proportion of un-
treated diabetic patients with normal PT, aPTT and platelet counts was 60.0%, 7.5
and 92.5%, respectively. There was a significant shortening of aPTT in untreated
diabetic as compared to both treated and non-diabetic controls (P < 0.001).
Shortening of aPTT in untreated type II diabetic patients might be useful marker in
patients with diabetes. Therefore, monitoring the aPTT in newly diagnosed diabetic
patients is important.
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11 Abstract
12 Background The incidence of cardiovascular disease due to thrombosis is 2–4 folds greater in diabetic patients. Prothrombin
13 time, activated partial thromboplastin time and platelet count are hematological indices that give an insight into the coagulation
14 status. Hence, this study aims to assess the coagulation status of type II diabetic patients.
15 Methods A comparative cross-sectional study was conducted at Bahir Dar Felege Hiwot referral hospital, Northwest Ethiopia. A
16 total of 40 treated type II diabetic, 40 untreated diabetics and 40 non-diabetic subjects were included. After taking informed
17 consent, structured questionnaire was used to collect socio-demographic data. Following interview, 4 ml of blood was collected
18 to determine PT, aPTTand platelet count of the three groups. The data were entered into SPSS version 20 and analyzed. One-way
19 ANOVAwas used to compare means of PT, aPTTand platelet count among the groups. A P value less than 0.05 was considered
20 as statistically significant.
21 Results The mean aPTTof non-diabetic, treated and untreated type II diabetic patient was 32.8 ± 4.12 s, 34.4 ± 5.3 s, and 25.42 ±
22 8.46 s, respectively. The proportion of untreated diabetic patients with normal PT, aPTT and platelet counts was 60.0%, 7.5 and
23 92.5%, respectively. There was a significant shortening of aPTT in untreated diabetic as compared to both treated and non-
24 diabetic controls (P < 0.001).
25 Conclusions Shortening of aPTT in untreated type II diabetic patients might be useful marker in patients with diabetes. Therefore,
26 monitoring the aPTT in newly diagnosed diabetic patients is important.
27 Keywords Activated partial thromboplastin time . Platelet count . Prothrombin time . Type II diabetes mellitus . Bahir Dar .
28 Ethiopia
29
30Background
31Diabetes mellitus (DM) is metabolic diseases characterized by
32hyperglycemia resulting from defects in insulin secretion, in-
33sulin action, or both. Etiologically, diabetes is classified into
34two; type I and type II diabetes mellitus [1]. Type II diabetes
35mellitus, previously called non-insulin dependent diabetes
36mellitus, is characterized by decreased insulin sensitivity
37which can subsequently provoke decreased insulin secretion
38as a result of Beta-cell loss [2].
39The International Diabetes Federation (IDF) has predicted
40that the number of individuals with diabetes will increase from
41382 million in 2013 to 592 million in 2035, with 77% of the
42disease burden in lowland middle-income countries. Similarly,
43the IDF have also reported that in Ethiopia about 2 million
44people are expected to live with DM with the national preva-
45lence of 4.4% in 2013 [3, 4]. Type II diabetic patients are at high
46risk for the development of thrombosis and bleeding disorders.
47Approximately 80% of patients die as a result of cardiovascular
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48 complications and its incidence due to thrombosis is 2–4 folds
49 greater than the general population [5].
50 Furthermore, prothrombin time (PT), activated partial
51 thromboplastin time (aPTT) and platelet are hematological in-
52 dices that give an insight into the coagulation status of patients.
53 PT is a screening test used to detect disorders involving the
54 activity of clotting factors (proteins) such as I, II, V, VII, and
55 X of the extrinsic and common pathways while aPTT is used to
56 screen for abnormalities of the intrinsic and common clotting
57 systems and to monitor the anticoagulant effect of circulating
58 heparin. It measures the activities of factors I, II, V, VIII, IX, X,
59 XI, and XII of the intrinsic and common pathways [6].
60 However, there was no previous study that had been conducted
61 concerning on evaluating the coagulation status of diabetes
62 type II patients in the study area. Therefore, this study was
63 aimed to assess the prothrombin time, activated partial throm-
64 boplastin time and platelet counts of type II diabetes mellitus at
65 Bahir Dar Felege Hiwot referral hospital, Northwest Ethiopia.
66 Methods
67 Study setting and study population
68 A comparative cross-sectional study design was used to deter-
69 mine and compare PT, aPTT and PLT count of treated type II
70 DM, untreated DM and healthy individuals. The study was
71 conducted at Bahir Dar Felege Hiwot referral hospital from
72 March to April, 2015. This hospital is found in Bahir Dar town
73 which is 546 km from Addis Ababa in the Northwest
74 Ethiopia. The hospital provides services for more than 800
75 new out patients and 5–10 follow-up diabetes patients per day.
76 According to the rules of thumb that has been recommend-
77 ed by VanVoorhis and Morgan, sample size of 30 for 80%
78 power in each group are required to detect real differences
79 [7]. Based on this suggestion, a total of 120 conveniently
80 selected study subjects (40 treated type II DM patients, 40
81 untreated DM patients and 40 healthy controls) aged 30–
82 60 years were included in this study. The study subjects were
83 categorized in to three groups. Group I consisted of type II
84 diabetic patients who had already started their non-insulin
85 hypoglycemic drugs while group II included untreated newly
86 diagnosis diabetic patients (fasting blood sugar (FBS) >
87 126 mg/dl or random blood sugar (RBS) > 180 mg/dl, had
88 symptoms of diabetic and were confirmed by physician). On
89 the other hand group II included those individuals who were
90 apparently healthy and came to the hospital for medical check-
91 up (Individuals who did nott have a diabetic history or symp-
92 tom, any anticoagulant therapy, hypertensive, clinically prov-
93 en liver dysfunction and whose FBS level was between
94 70 mg/dl and110 mg/dl) were studied. Treated type II diabetic
95 and newly diagnosis DM patients on warfarin or heparin or
96 any other anticoagulation therapy such as aspirin, and with
97other complications such as history of liver diseases, liver
98dysfunction, on hepatotoxic drugs, history of alcohol intake
99or cigarette smoking, hypertensive and psychic patients were
100excluded from the study. Apparently healthy individuals with
101any of DM symptom or who had taken any anticoagulant drug
102or who have a history of hypertensive were also excluded
103from the study.
104Data collection and laboratory analysis
105Sociodemographic data were collected with face to face inter-
106view after taking informed written consent followed by 4 ml of
107fasting blood collection. Then 1.8 ml blood sample was deliv-
108ered into a test tube containing 0.2 ml tri-sodium citrate antico-
109agulant to keep 9:1 ratio of blood to anticoagulant. The blood
110was then centrifuged at approximately 3000 rpm for 15 min to
111prepare platelet poor plasma for aPTT and PT analysis. aPTT
112and PTwere analyzed by using Huma Clot Duo plus instrument
113(HUMAN GmbH, Germany) [8]. The remaining blood was
114delivered into EDTA test tube for platelet count using Huma-
115Count hematology analyzer (HUMAN GmbH, Germany) [9].
116To assure the quality of laboratory tests; proper labeling,
117patient identification and sample collection procedures were
118strictly followed. Quality control samples were also analyzed
119along the study subject samples. Appropriate recording, re-
120sults interpretation and cross checking the result with its cor-
121respondence labeling were performed. Completeness of data
122was checked daily.
123Statistical analysis
124Data were entered in to SPSS version 20 for analysis.
125Descriptive statistics were used to describe the study groups.
126The Kolmogrov-Smirnov normality test was conducted and it
127showed that continuous variables were normally distributed
128among each group, so parametric tests were used. All contin-
129uous variables results were presented as mean ± standard de-
130viation (SD) for each group. One-way ANOVA was used to
131compare means of PT, aPTT and platelet count among the
132groups. Tables and graphs were used to present the results.
133A P < 0.05 was considered as statistically significant.
134Data availability All data supporting these findings is
135contained within the manuscript.
136Results
137Characteristics of study participants
138A total of 120 study participants were included in this study.
139Of which, 40 were untreated DM patients, 40 were treated
140type II DM patients and the remaining 40 were healthy
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141 controls. Theminimum andmaximum age was 30 and 56with
142 the mean age of 40.57 ± 7.47 years in untreated, 37.80 ±
143 5.9 years in treated and 39.27 ± 6.59 years in healthy controls.
144 About 62.5%, 75 and 62.5% of untreated DM, treated type II
145 DM and non-diabetic controls were married, respectively.
146 Furthermore, 70% of treated type II DM patients were treated
147 using non-insulin hypoglycemic drug for less than 5 years and
148 only 2% of treated type II DM were treated for more than
149 10 years with similar drug (Table 1).
150Laboratory findings
151The proportion of untreated diabetic patients with normal PT,
152aPTT and platelet counts was 60.0%, 7.5 and 92.5%, respec-
153tively. Whereas, the proportion of treated diabetic patients
154with normal PT, aPTT and platelet counts was 85%, 95%,
155and 82.5%, respectively. Moreover, the proportion of treated
156diabetic patients with decreased aPTT and platelet count was
1572.5 and 7.5%, respectively. There was no decreased PT value
158in treated DM patients. Whereas, the proportion of untreated
159diabetic patients with decreased PT, aPTT and platelet count
160was 20%, 85 and 7.5% of respectively (Fig. 1a, b & c)).
161The mean aPTTof non-diabetic, treated and untreated type
162II diabetic patient was 32.8 ± 4.12 s, 34.4 ± 5.3 s, and 25.42 ±
1638.46 s, respectively. Similarly, the mean PT of non-diabetic
164controls, treated type II DM and untreated DM were 14.28 ±
1651.50 s, 14.65 ± 2.50 s and 13.54 ± 3.44 s, respectively.
166Moreover, the platelet count of non-diabetic control, treated
167type II DM, and untreated DM were 251,000 ± 71,964,
168254,000 ± 95,077 and 250,000 ± 75,546, respectively. The
169study subjects had significantly different aPTT among the
170three groups in the ANOVA test (F: 60.7; P < 0.001).There
171was a significant shortening of aPTT in untreated diabetic as
172compared to both treated and non-diabetic controls (P <
1730.001). However, the mean aPTT, PT and platelet count were
174not significant between treated type II DM patients and non-
175diabetic individuals (P > 0.05) (Table 2).
176Discussion
177In this study, non-diabetic, treated and untreated diabetic have a
178mean aPTT of 32.79 ± 4.12 s, 34.45 ± 5.35 s, and 25.42 ±
1798.46 s, respectively. There was a significant shortening of
180aPTT in untreated diabetic patients compared to either treated
181or non-diabetic individuals (P < 0.001). Similar findings were
182reported by Zhao et al... among patients in China [10], by
183Chavan et al. in India [11], Acang et al. in Indonesia [12] and
184Ankalayya et al in India [13] that described shortening of aPTT
185in type II DM patients is a high risk of hypercoagulable state.
t1:1 Table 1 Demographic data of treated, untreated diabetic and non-
diabetic study subjects
t1:2 Parameters Untreated
DM
Treated type II
DM
Healthy
controls
t1:3 N (%) N (%) N (%)
t1:4 Gender
t1:5 Male 25 (62.5%) 25 (62.5%) 24 (60.0%)
t1:6 Female 15 (37.5%) 15 (37.5%) 16 (40.0%)
t1:7 Age in years
t1:8 30–40 23 (57.5%) 30 (75.0%) 26 (65.0%)
t1:9 41–50 12 (30%) 9 (22.5%) 13 (32.5%)
t1:10 51–60 5 (12.5%) 1 (2.5%) 1 (2.5%)
t1:11 Residence
t1:12 Urban 23 (57.5%) 28 (70.0%) 29 (72.5%)
t1:13 Rural 17 (42.5%) 12 (30.0%) 11 (27.5%)
t1:14 Marital status
t1:15 Married 25 (62.5%) 30 (75.0%) 25 (62.5%)
t1:16 Not married 15 (37.5%) 10 (25.0%) 15 (37.5%)
t1:17 Educational status
t1:18 Illiterate 12 (30.0%) 17 (42.5%) 8 (20.0%)
t1:19 Elementary school 6 (15.0%) 6 (15.0%) 7 (17.5%)
t1:20 High school 11 (27.5%) 9 (22.5%) 10 (25.0%)
t1:21 University
graduated
11 (27.5%) 8 (20.0%) 15 (37.5%)
t1:22 Duration of treatment
t1:23 0-5 years NA 28 (70.0%) NA
t1:24 6-10 years NA 10 (25.0%) NA
t1:25 > 10 years NA 2 (5.0%) NA
N.B: DM, diabetic miletus; NA, not applicable
Fig. 1 Profile of PT, aPTT and platelet count in healthy controls, treated and untreated diabetic study subjects
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186 This may happen due to the glycation of intrinsic clotting fac-
187 tors caused by the presence of persistent hyperglycemia in un-
188 treated DM patients. Persistent hyperglycemia may result the
189 glycation of intracellular and extracellular protein that will
190 change the normal functioning of these proteins which affect
191 their clotting capacity [14]. Thus, glycation of clotting factors
192 may result the activation of inactive intrinsic factors which
193 finally results the shortening of aPTT [15].
194 However, PT of untreated DM patients was not found sig-
195 nificantly associated in this study when compared to treated
196 type II DM patients (P = 0.274) and non-diabetic individuals
197 (P = 0.759). The insignificant PT results support the hypothe-
198 sis that there is less involvement of the extrinsic pathway in
199 hypercoagulability state in diabetic conditions due to the fact
200 that injury occurring to the vascular system in diabetic patients
201 does not involve the release of tissue factor from outside of the
202 vascular system [16]. APTT but not PT would be affected by
203 the glycation method. Hypercoagulability detected by short-
204 ened APTT values was independently associated with venous
205 thromboembolism (VTE) and hypothesized that shortened
206 APTT could be considered as a risk marker for VTE [17].
207 This entails that APTT is a better predictor of hypercoagulable
208 state than PT in T2DM patients [18] which have any impact
209 on the management of these patients.
210 The current study also showed that there was no significant
211 difference of the mean PT, aPTT and platelet count between
212 treated and non-diabetic individuals (P > 0.05). This might be
213 due to the effect of non- insulin hypoglycemic drug on glucose
214 level which in turn prevents glycation process in treated DM
215 patients.
216 In this study, the mean PT and platelet count of treated;
217 untreated diabetic patients and non-diabetic individuals had
218shown no significant difference among the groups (P >
2190.05). Similarly, studies conducted in Iran by Soltani et al.
220[16] and in Nigeria by Ifeanyi et al. [19] reported no signifi-
221cant difference of PT findings among the groups, and Ephraim
222et al. [20] also reported mean platelet count was within the
223normal range among study subjects in Ghana.
224Moreover, 12.5% of untreated diabetic had a decreased PT
225compared to no decreased PT in treated diabetic patients.
226About 85% of untreated diabetic had a decreased aPTTwhere-
227as only 2.5% of treated diabetic had a decreased aPTT. This
228finding indicates that those treated type II diabetic patients had
229properly control their blood glucose level than untreated indi-
230viduals. This may be due to association of glycation, a non-
231enzymatic binding of glucose on protein, with the persistence
232hyper glycemia that could change the normal function of the
233intrinsic factors (aPTT) and the extrinsic factors (PT) [14].
234Conclusions
235There was a significant shortening of aPTT in untreated dia-
236betic patients as compared with treated and non-diabetic
237groups. Therefore, shortening of aPTT in untreated type II
238diabetic patients might be useful marker in patients with dia-
239betes. Monitoring of the aPTT in newly diagnosed diabetic
240patients is important to prevent hypercoagulation.
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t2:1 Table 2 Mean of PT, aPTT and platelet count of treated and untreated
diabetic study subjects
t2:2 Parameters Untreated DM Treated type II DM P Value
t2:3 Mean ± SD Mean ± SD
t2:4 PT/ Sec 13.54 ± 3.44 14.65 ± 2.50 0.274
t2:5 aPTT/ Sec 25.42 ± 8.46 34.4 ± 5.35 <0.001
t2:6 Platelet count/ μl 250,000 ± 75,546 254,000 ± 95,077 0.759
t2:7 Untreated DM Non-diabetic P value
t2:8 Mean ± SD Mean ± SD
t2:9 PT/ Sec 13.54 ± 3.44 14.28 ± 1.50 0.964
t2:10 aPTT/ Sec 25.42 ± 8.46 32.79 ± 4.12 <0.001
t2:11 Platelet count/ μl 250,000 ± 75,546 251,000 ± 71,964 0.933
t2:12 Treated Type II DM Non-diabetic P value
t2:13 Mean ± SD Mean ± SD
t2:14 PT/ Sec 14.65 ± 2.50 14.28 ± 1.50 0.405
t2:15 aPTT/ Sec 34.4 ± 5.35 32.79 ± 4.12 0.951
t2:16 Platelet count/ μl 254,000 ± 95,077 251,000 ± 71,964 0.933
N.B: P value is derived from one way ANOVA test, numeric numbers in
bold indicate the presence of significant association
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266 Abbreviations aPTT, activated partial thromboplastin time; CVD, car-
267 diovascular disease; DM, diabetes mellitus; FBS, fasting blood sugar;
268 IDF, international diabetic federation; PT, prothrombin time; RBS, ran-
269 dom blood sugar
270
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